Latest News from EU FP7: Updated February 9th 20101

The 1st EACR-OECI Joint Training Course accreditated by ACOE

New communication resources
Working Groups and Activities
Upcoming Events
General Assemblies
Past Events
Contact Us
Working Groups
The work of the Organization is conducted through scientific meetings, consultations and working groups with funds of the OECI. A limited number of working groups and special activities are designed to sustain the main objectives of the Organization, which are:
WGA&D;: Working Group Accreditation and Designation of cancer centers in Europe
Chairperson: Mahasti Saghatchian

WGE&T;: Working Group Education & Training
Chairperson: Angelo Paradiso

The Education and Training Working Group: “E&T; WG” aims to stimulate the international mobility for young scientists, to improve the capabilities of research and development and to promote continuing education for experienced scientists and clinicians.
The main goal of the E&T; WG is to promote the establishment of a European Area for E&T; in the cancer field, to stimulate better relationship among the members of the GEIE-OECI (the Group) and defining in the meantime a better connection with external related bodies.
With the plan of activities of the E&T; WG the OECI hopes to contribute to give a practical answer to the Lisbon goals, to tackle fragmentation of training and to share knowledge and facilities among CCC, to facilitate the launch of new research initiatives, to reinforce existing successful actions, to improve knowledge on new emerging fields, to exchange personnel with industries and vice-versa.

WGCB: Cancer Biobanks
Chairperson: Peter Riegman

The OECI Cancer Biobanks working group has the task to standardize and harmonize the collection of biological samples in European Comprehensive Cancer centers for cancer applications.

WGMP: Working Group Molecular Pathobiology
Chairperson: Antonio Llombart-Bosch

(in progress)

START Project Activity
Chairperson: Lisa Licitra

START stands for “State-of-the-Art Oncology in Europe”. In fact, it is meant to be an online data base on state-of-the-art knowledge about cancer diagnostics and treatment, with a European perspective. This means that the statements on main clinical “options” are codified and accompanied by a codified “levels of evidence” and “type of basis”, according to a classification originally devised (Figure 1). The background has been detailed in the literature (Ann. Oncol. 1999; 10: 769-774).
START is an independent Program. It was established in 1995 within the ESO. As from September 2002, it is one of the services also supported by Alleanza Contro il Cancro (“Alliance Against Cancer” - ACC), the Italian cancer network, under the auspices of the Italian Health Ministry. Formally, START is a data base, freely accessible on the Internet at It contains chapters on single human malignant neoplasms, as well as some chapters on cancer-related topics (antiemetic therapy, pain therapy, and more). Original chapters are written in English, subsequently translated into Italian and eventually adapted (only in Italian) for patients and non professionals in general

WIN Project Activity
Chairperson: Thomas Tursz

Today there are more than 14,000,000 new cancers each year world wide, and less than 50% are cured. The main cause is late detection and inappropriate treatment based on statistical population approaches. The shift from past to future medicine based on prevention, early diagnosis and efficient individualized treatments could be dramatically accelerated from 50 years to a 3-5 year timeline, through a coordinated efficient worldwide initiative bringing together the élite of academic industry and a coordinated governmental strategy. To this aim, the WIN Consortium (worldwide innovative networking in cancer personalized medicine) is a joint initiative of the Institut Gustave Roussy and the University of Texas M. D. Anderson Cancer Center (MDACC), in association with 26 élite leading cancer care institutions in Europe, United States of America, Canada, Middle East and Asia. All European institutes are OECI members. The major goal of the WIN Consortium is to accelerate translation of ground-breaking discoveries made in personalized cancer medicine from the bench to the bedside and to promote new types of interactions between academy and industry worldwide.
This is a worldwide initiative, across the continents, and the WIN Consortium aims to build new strategic alliances in oncology, to improve early diagnosis of cancer, and to establish new treatment strategies based on rational individualized selection of treatments.
The management of the WIN Consortium is assured by Dr. Vladimir Lazar from IGR (France), in his capacity of co-ordinator of the WIN Consortium and Chairman of the Steering Committee, and by Pr. John Mendelsohn from MDACC (USA), in his capacity of President of the WIN Consortium. The management proposes a strategic plan based on the most advanced scientific and technologic achievements and brings together worldwide key opinion leaders in oncology.
The WIN Consortium is extremely focused on five objectives:
1. early diagnosis as the most efficient way to improve clinical outcome;
2. individualized treatment and therapeutic combinations based on innovative technologies available within the consortium;
3. strategic positioning with pharmaceutical companies with innovative drug associations and efficient clinical trials conducted simultaneously across the continents;
4. standardisation, harmonization and worldwide coordination of academics;
5. education and scientific dissemination through its annual WIN symposium

The WIN consortium is an operational organization that has decided to join forces and knowledge in order to considerably improve health care in oncology and to lead to important societal benefits in terms of cost of cancer health care.

Developed and maintained by MEDINFO - DIST
Comments on the web
Web site optimized for Firefox and Explorer Browsers Updated: 13 January 2011
Comments on the contents